Legal Representation
Attorney
Shane Percival
USPTO Deadlines
Next Deadline
47 days remaining
Final Refusal E-Mailed
Due Date
February 05, 2026
Extension Available
Until May 05, 2026
Application History
14 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 5, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Nov 5, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Nov 5, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Sep 19, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 19, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 19, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 16, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jun 16, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Mar 19, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 19, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 19, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 13, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 27, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 12, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 036
Financial Services, namely, providing debt and equity financing to bio-pharmaceutical, biotechnology, healthcare, drug delivery, healthcare diagnostic, and medical device companies; Investment advisory services; Financial services, namely, providing structured financing for intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, providing structured financing to ownership entities of intellectual property assets, namely, corporations, research institutions, and inventors; Financial services, namely, investment in intellectual property assets, namely, the licensing of, and purchasing an ownership interest in, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, investment in assets protected by intellectual property, namely, the licensing of, and purchasing an ownership interest in, revenue streams from intellectual property protected assets; Financial services, namely, the formation and management of pool investment vehicles and investment accounts for the purpose of investment in debt and equity interests in bio-pharmaceutical companies, biotechnology companies, healthcare companies, drug delivery companies, healthcare diagnostic companies, medical device companies, and intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets.
Additional Information
Pseudo Mark
CR GROUP PREMIERE
Classification
International Classes
036